Status:
Ready to upload
Record number:
1637
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Of 8,953 women (age 18-50) who were transfused, thirty-one (0.35%) delayed RBC alloimmunization reports were notified in 30 female patients.
Time to detection:
Retrospective study
Alerting signals, symptoms, evidence of occurrence:
In order to evaluate the incidence of delayed RBC alloimmunization in the population of 18 to 50- year old transfused women, all adverse transfusion reaction reports from all hospitals of the Rhone-Alpes area collected during a period of 3 years were studied. The specificity of the RBC antibodies, the blood product involved and the imputability were considered. From January 1st 2010 to December 31st 2012, 8,953 women (age range 18 to 50) were transfused. Thirty-one delayed RBC alloimmunization reports were notified in 30 female patients. In the other cases of alloimmunization, the antibodies were not caused by antigens of the Rhesus or Kell systems (antigens C, E, c, e and K); the most common antibodies were anti-S and anti-Kpa which occurred in 7 cases each. The blood components involved were RBC concentrates in 28 cases (90.3%), apheresis platelet concentrate in one case and pooled platelet concentrates in two cases. Three cases of RBC alloimmunization were detected after transfusion of platelet concentrates: anti-Jka (one case), anti-DAU5 (one case) with two pooled platelet concentrates and anti-E (one case) with one apheresis platelet concentrate.
Demonstration of imputability or root cause:
The imputability of the blood component was certain in 13 cases (42.0%), probable in 17 cases (54.8%) and possible in one case (3.2%).
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Keywords:
Suggest new keywords:
anti-S, anti-Kp(a), anti-Jk(a), anti-DAU5, anti-E
Suggest references:
Moncharmont, P, Barday G and Meyer, F. (2015). Red blood cell alloimmunisation in 18 to 50-year old transfused women: a 3-year study. Blood Transfus 13:345-6
Expert comments for publication:
The matching of RBC concentrates for the Rhesus and Kell systems has proven to be efficient; only 2 female recipients acquired new RBC antibodies (anti-c and anti-K) after transfusion.